Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Global Antibiotic Research and Development Partnership

- PMLiVE

NICE recommends better targeting of antibiotics for suspected sepsis

It is hoped that the new guidance will reduce the risk of antibiotic resistance by ensuring antibiotics are targeted to those at the greatest risk

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

MIT researchers identify new class of antibiotic candidates using AI

MRSA is a drug-resistant bacterium responsible for 10,000 deaths a year in the US

- PMLiVE

National surveillance data reveals increase in antibiotic resistant infections in England

The number of deaths due to severe antibiotic resistant infections also increased in 2022

- PMLiVE

Shionogi to acquire Qpex Biopharma for approximately $140m

The deal signifies a notable expansion to the Japanese drugmaker’s antimicrobial pipeline

- PMLiVE

Shionogi’s cefiderocol shows efficacy against difficult-to-treat bacterial infections

Antimicrobial resistance has been declared as one of the top ten threats to global health

- PMLiVE

European MPs call for urgent action against antimicrobial resistance

It is estimated that AMR could lead to as many as ten million deaths each year by 2050

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide

The licence and collaboration agreements will provide 135 countries access to cefiderocol

- PMLiVE

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments

- PMLiVE

Shionogi and F2G partner to develop antifungal treatment olorofim

The deal, worth up to $480m, involves the first novel antifungal treatment developed in the last 20 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links